Allogeneic HSCT Outcomes Assessment

Primary end-points were the cumulative incidences of NRM and relapse (defined as disease recurrence according to marrow morphology, flow cytometry, cytogenetics, fluorescence in situ hybridization and polymerase chain reaction). Secondary end-points were: full donor-type engraftment, the cumulative incidences of grades ≥2 aGvHD and cGvHD, the probability of GvHD/relapse-free survival (GRFS) and CRFS. Immune reconstitution was monitored by means of T-cell counts and specific responses to pathogens. The method and evaluation of clones were described elsewhere [18 (link)].

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

Massei M.S., Capolsini I., Mastrodicasa E., Perruccio K., Arcioni F., Cerri C., Gurdo G., Sciabolacci S., Falzetti F., Zei T., Iacucci Ostini R., Brogna M., Panizza B.M., Saldi S., Merluzzi M., Tognellini R., Marchesi M., Minelli O., Aristei C., Velardi A., Pierini A., Ruggeri L., Martelli M.F., Carotti A, & Caniglia M. (2023). HLA-haploidentical hematopoietic stem cells transplantation with regulatory and conventional T-cell adoptive immunotherapy in pediatric patients with very high-risk acute leukemia. Bone Marrow Transplantation, 58(5), 526-533.

Publication 2023

Clones Donor Flow cytometry Fluorescence in situ hybridization Immune reconstitution Marrow Pathogens Polymerase chain reaction Recurrence Relapse T cell

Corresponding Organization : Ospedale Santa Maria

Other organizations : University of Perugia

Top 5 similar protocols

Variable analysis

independent variables

Not explicitly mentioned

dependent variables

Cumulative incidences of NRM (non-relapse mortality)
Cumulative incidences of relapse (defined as disease recurrence according to marrow morphology, flow cytometry, cytogenetics, fluorescence in situ hybridization and polymerase chain reaction)
Full donor-type engraftment
Cumulative incidences of grades ≥2 aGvHD (acute Graft-versus-Host Disease)
Cumulative incidences of cGvHD (chronic Graft-versus-Host Disease)
Probability of GvHD/relapse-free survival (GRFS)
Probability of CRFS (not defined)
T-cell counts
Specific responses to pathogens

control variables

Not explicitly mentioned

positive controls

Not specified

negative controls

Not specified

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!